BioLineRx Ltd Total Liabilities
BioLineRx Ltd total liabilities. Based on the latest financial reports, BioLineRx Ltd (BLRX) has total liabilities worth $16.86 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check financial resilience of BioLineRx Ltd to evaluate the company's liquid asset resilience ratio.
Total Liabilities of BioLineRx Ltd (2008–2025)
Total liabilities of BioLineRx Ltd from 2008 to 2025. This chart illustrates how BioLineRx Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore BLRX strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.
BioLineRx Ltd Competitors by Total Liabilities
The table below lists competitors of BioLineRx Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Baselode Energy Corp
V:FIND
|
Canada | CA$5.71 Million |
|
Landmarks Bhd
KLSE:1643
|
Malaysia | RM376.30 Million |
|
Clinical Laserthermia Systems AB (publ)
ST:CLS-B
|
Sweden | Skr22.07 Million |
|
Bhandari Hosiery Exports Limited
NSE:BHANDARI
|
India | Rs1.34 Billion |
|
SSH Group Ltd
AU:SSH
|
Australia | AU$31.15 Million |
|
Lease IT Public Company Limited
BK:LIT
|
Thailand | ฿536.69 Million |
|
Tectona
TA:TECT
|
Israel | ILA7.16 Million |
Liability Composition Analysis (2008–2025)
This chart breaks down BioLineRx Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see BLRX total asset value.
Liquidity & Leverage Metrics
BioLineRx Ltd Total Liabilities Ratios Explained
BioLineRx Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.20 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.22 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.50 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how BioLineRx Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for BioLineRx Ltd (2008–2025)
The table below shows the annual total liabilities of BioLineRx Ltd from 2008 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $17.56 Million | -30.99% |
| 2024-12-31 | $25.45 Million | -49.81% |
| 2023-12-31 | $50.70 Million | +98.50% |
| 2022-12-31 | $25.54 Million | +91.99% |
| 2021-12-31 | $13.30 Million | -47.33% |
| 2020-12-31 | $25.26 Million | +25.13% |
| 2019-12-31 | $20.19 Million | +35.37% |
| 2018-12-31 | $14.91 Million | +84.46% |
| 2017-12-31 | $8.08 Million | +106.65% |
| 2016-12-31 | $3.91 Million | +5.96% |
| 2015-12-31 | $3.69 Million | -16.09% |
| 2014-12-31 | $4.40 Million | -46.76% |
| 2013-12-31 | $8.27 Million | -11.47% |
| 2012-12-31 | $9.34 Million | +37.18% |
| 2011-12-31 | $6.81 Million | +6.40% |
| 2010-12-31 | $6.40 Million | -41.23% |
| 2009-12-31 | $10.88 Million | +10.09% |
| 2008-12-31 | $9.89 Million | -- |
About BioLineRx Ltd
BioLineRx Ltd., a biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes GLIX1, an oral, small molecule targeting DNA damage response in glioblastoma and other cancers; and APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the tr… Read more